HEPAVAC

Cancer Vaccine development for Hepatocellular Carcinoma

Coordinatore	ISTITUTO NAZIONALE TUMORI Fondazione Pascale    more  Organization address address: Via Mariano Semmola 142 city: NAPOLI postcode: 80131 contact info Titolo: Dr. Nome: Vincenza Cognome: Farinari Email: send email Telefono: 390816000000
Nazionalità Coordinatore	Italy [IT]
Sito del progetto	http://www.hepavac.eu
Totale costo	8˙200˙536 €
EC contributo	5˙996˙110 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2018-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ISTITUTO NAZIONALE TUMORI Fondazione Pascale  Organization address address: Via Mariano Semmola 142 city: NAPOLI postcode: 80131 contact info Titolo: Dr. Nome: Vincenza Cognome: Farinari Email: send email Telefono: 390816000000	IT (NAPOLI)	coordinator	1˙845˙500.00
2	IMMATICS BIOTECHNOLOGIES GMBH  Organization address address: PAUL EHRLICH STR 15 city: TUEBINGEN postcode: 72076 contact info Nome: Maria Cognome: Poulada Email: send email Telefono: +49 7071 5397 710 Fax: +49 7071 5397 900	DE (TUEBINGEN)	participant	1˙934˙200.00
3	EBERHARD KARLS UNIVERSITAET TUEBINGEN  Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Prof. Nome: Hans-Georg Cognome: Rammensee Email: send email Telefono: +49 7071 29 87628 Fax: +49 7071 29 5653	DE (TUEBINGEN)	participant	700˙840.00
4	UNIVERSITA DEGLI STUDI DELL'INSUBRIA  Organization address address: Via Ravasi 2 city: VARESE postcode: 21100 contact info Titolo: Prof. Nome: Roberto Cognome: Accolla Email: send email Telefono: +39 0332217606 Fax: +39 0332217608	IT (VARESE)	participant	410˙796.80
5	CUREVAC GMBH  Organization address address: PAUL EHRLICH STRASSE 15 city: TUEBINGEN postcode: 72076 contact info Titolo: Dr. Nome: Oliver Cognome: Schlüter Email: send email Telefono: 4970720000000	DE (TUEBINGEN)	participant	312˙540.00
6	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Prof. Nome: Danila Cognome: Valmori Email: send email Telefono: +33 2 40 67 97 26 Fax: +332 40 67 97 63	FR (PARIS)	participant	303˙520.00
7	THE UNIVERSITY OF BIRMINGHAM  Organization address address: Edgbaston city: BIRMINGHAM postcode: B15 2TT contact info Titolo: Ms. Nome: May Cognome: Chung Email: send email Telefono: 441214000000 Fax: 441214000000	UK (BIRMINGHAM)	participant	254˙914.00
8	UNIVERSIDAD DE NAVARRA  Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 contact info Titolo: Mr. Nome: Fco. Javier Cognome: Irigoyen Barrio Email: send email Telefono: 34948176748 Fax: 34948175223	ES (PAMPLONA)	participant	117˙950.00
9	UNIVERSITAIR ZIEKENHUIS ANTWERPEN  Organization address address: WILRIJKSTRAAT 10 city: EDEGEM postcode: 2650 contact info Titolo: Prof. Nome: Sven Cognome: Francque Email: send email Telefono: +32 38214572 Fax: +32 3 8214478	BE (EDEGEM)	participant	115˙850.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%. The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC patients after loco-regional ablative therapy. HepaVac is an European consortium of academic, SME and pharmaceutical company partners with complementary and substantial expertise in cancer immunotherapy and vaccine development. The main objective of HepaVac is to develop a novel cancer vaccine approach for HCC based on epitopes naturally processed and presented by HLA class I and II (HLA-ligandome), to elicit both CD4 T helper and CD8 CTL tumor-specific effector and memory responses. The HCC HLA-ligandome will be identified in primary tumor tissues using a combined and integrated approach, developed and thoroughly validated by Partners #2 and #5. The selected peptide epitopes will constitute the candidate cancer vaccine for HCC, aiming at covering the broadest haplotype diversity with a multi-epitope and multi-TAA strategy. T cell epitopes derived from universal TAA and unique patient-specific mutated antigens will allow the design of a prime-boost vaccine strategy based either on a prime-boost schedule made of an “off-the-shelf” T cell epitope cocktail or on a schedule where the boost is complemented by a “personalized” T cell epitope cocktail. Both epitope cocktails will be adjuvanted in a novel and potent immunomodulator developed by Partner #6. Such a vaccination strategy will be tested in a randomized controlled multi-center phase I/II human clinical trial, assessing as primary endpoints safety and induction of specific cellular immune responses and, as secondary endpoints, OS and PFS of patients receiving the vaccine after tumor ablation vs tumor ablation alone.'